Contents

Search

elvitegravir (GS 9137, EVG/c)

Indications: - treatment of HIV1 in combination with HIV medications that require boosting - component of elvitegravir/emtricitabine/cobicistat/tenofovir (Quad) Contraindications: - avoid during pregnancy (data insufficient) [2] Adverse effects: - nausea, diarrhea - otherwise well tolerated [3] Laboratory: - elvitegravir in serum/plasma Mechanism of action: - integrase inhibitor

Interactions

drug adverse effects of antiretroviral agents

General

integrase inhibitor; integrase strand transfer inhibitor (InSTI)

Database Correlations

PUBCHEM correlations

References

  1. Wikipedia: Elvitegravir http://en.wikipedia.org/wiki/Elvitegravir
  2. Zuger A Use of Antiretroviral Drugs in Pregnancy. Physician's First Watch, April 22, 2014 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org - Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. 2014. AIDSinfo. Clinical Guidelines Portal. March 28, 2014. http://aidsinfo.nih.gov/Guidelines/HTML/3/perinatal-guidelines/0 (corresponding NGC guideline withdrawn March 2016)
  3. Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015
  4. AIDSMAP: Elvitegravir http://www.aidsmap.com/Elvitegravir-GS-9137/page/1731274/

Component-of

cobicistat/elvitegravir/emtricitabine/tenofovir (Quad, Stribild, Genvoya)